Non-stroke Central Neurologic Manifestations in Antiphospholipid Syndrome
- 作者:Cécile M. Yelnik ; Elizabeth Kozora ; Simone Appenzeller
- 关键词:Antiphospholipid syndrome (APS) ; Antiphospholipid antibody ; Non ; thrombotic manifestations ; Neurological manifestations ; Systemic lupus erythematosus (SLE) ; Autoimmunity
- 刊名:Current Rheumatology Reports
- 出版年:2016
- 出版时间:February 2016
- 年:2016
- 卷:18
- 期:2
- 全文大小:349 KB
- 参考文献:1.Harris EN, Gharavi AE, Boey ML, Patel BM, Mackworth-Young CG, Loizou S, et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet Lond Engl. 1983;2(8361):1211–4.CrossRef
2.Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42(7):1309–11.PubMed CrossRef
3.Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost JTH. 2006;4(2):295–306.PubMed CrossRef
4.Kent M, Alvarez F, Vogt E, Fyffe R, Ng AK, Rote N. Monoclonal antiphosphatidylserine antibodies react directly with feline and murine central nervous system. J Rheumatol. 1997;24(9):1725–33.PubMed
5.Caronti B, Pittoni V, Palladini G, Valesini G. Anti-beta 2-glycoprotein I antibodies bind to central nervous system. J Neurol Sci. 1998;156(2):211–9.PubMed CrossRef
6.Shoenfeld Y, Nahum A, Korczyn AD, Dano M, Rabinowitz R, Beilin O, et al. Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. Lupus. 2003;12(6):436–42.PubMed CrossRef
7.••
Abreu MM, Danowski A, Wahl DG, Amigo M-C, Tektonidou M, Pacheco MS, et al. The relevance of “non-criteria” clinical
manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev. 2015;14(5):401–14. Last report of international experts’ conference, which summarizes experts’ conclusions on clinical non-criteria
manifestations of APS and their place in the classification criteria.PubMed CrossRef
8.Jacobson MW, Rapport LJ, Keenan PA, Coleman RD, Tietjen GE. Neuropsychological deficits associated with antiphospholipid antibodies. J Clin Exp Neuropsychol. 1999;21(2):251–64.PubMed CrossRef
9.Erkan D, Barbhaiya M, George D, Sammaritano L, Lockshin M. Moderate versus high-titer persistently anticardiolipin antibody positive patients: are they clinically different and does high-titer anti-beta 2-glycoprotein-I antibody positivity offer additional predictive information? Lupus. 2010;19(5):613–9.PubMed CrossRef
10.•
Kozora E, Erkan D, Zhang L, Zimmerman R, Ramon G, Ulug AM, et al. Cognitive dysfunction in antiphospholipid antibody (aPL)-negative systemic lupus erythematosus (SLE) versus aPL-positive non-SLE patients. Clin Exp Rheumatol. 2014;32(1):34–40. Proof of aPL implication in cognitive dysfunction independently of overlap with lupus.PubMed
11.Tektonidou MG, Varsou N, Kotoulas G, Antoniou A, Moutsopoulos HM. Cognitive deficits in patients with antiphospholipid syndrome: association with clinical, laboratory, and brain magnetic resonance imaging findings. Arch Intern Med. 2006;166(20):2278–84.PubMed CrossRef
12.•
Coín MA, Vilar-López R, Peralta-Ramírez I, Hidalgo-Ruzzante N, Callejas-Rubio JL, Ortego-Centeno N, et al. The role of antiphospholipid autoantibodies in the cognitive deficits of patients with systemic lupus erythematosus. Lupus. 2015;24(8):875–9. Recent paper with good methodology to evaluate the association between aPL and cognitive dysfunction.PubMed CrossRef
13.Krause I, Lev S, Fraser A, Blank M, Lorber M, Stojanovich L, et al. Close association between valvar heart disease and central nervous system
manifestations in the antiphospholipid syndrome. Ann Rheum Dis. 2005;64(10):1490–3.
14.Gómez-Puerta JA, Martín H, Amigo M-C, Aguirre MA, Camps MT, Cuadrado MJ, et al. Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus? Medicine (Baltimore). 2005;84(4):225–30.CrossRef
15.De Carvalho JF, Pasoto SG, Appenzeller S. Seizures in primary antiphospholipid syndrome: the relevance of smoking to stroke. Clin Dev Immunol. 2012;2012:981519.PubMed PubMedCentral
16.Krause I, Blank M, Fraser A, Lorber M, Stojanovich L, Rovensky J, et al. The association of thrombocytopenia with systemic
manifestations in the antiphospholipid syndrome. Immunobiology. 2005;210(10):749–54.
17.Etemadifar M, Dehghani L, Tahani S, Toghianifar N, Rahaimi M, Eskandari N.
Neurological
manifestations in patients with antiphospholipid syndrome. Iran J Neurol. 2013;12(4):172–5.
18.Appenzeller S, Yeh S, Maruyama M, Barros SM, de Carvalho JF. Chorea in primary antiphospholipid syndrome is associated with rheumatic fever. Rheumatol Int. 2012;32(9):2857–61.PubMed CrossRef
19.Cervera R, Piette J-C, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: clinical and immunologic
manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46(4):1019–27.PubMed CrossRef
20.Sherer Y, Hassin S, Shoenfeld Y, Levy Y, Livneh A, Ohry A, et al. Transverse myelitis in patients with antiphospholipid antibodies—the importance of early diagnosis and treatment. Clin Rheumatol. 2002;21(3):207–10.PubMed CrossRef
21.Chapman J, Abu-Katash M, Inzelberg R, Yust I, Neufeld MY, Vardinon N, et al. Prevalence and clinical features of dementia associated with the antiphospholipid syndrome and circulating anticoagulants. J Neurol Sci. 2002;15(203–204):81–4.CrossRef
22.Denburg SD, Carbotte RM, Ginsberg JS, Denburg JA. The relationship of antiphospholipid antibodies to cognitive function in patients with systemic lupus erythematosus. J Int Neuropsychol Soc JINS. 1997;3(4):377–86.PubMed
23.Leritz E, Brandt J, Minor M, Reis-Jensen F, Petri M. Neuropsychological functioning and its relationship to antiphospholipid antibodies in patients with systemic lupus erythematosus. J Clin Exp Neuropsychol. 2002;24(4):527–33.PubMed CrossRef
24.Menon S, Jameson-Shortall E, Newman SP, Hall-Craggs MR, Chinn R, Isenberg DA. A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum. 1999;42(4):735–41.PubMed CrossRef
25.Conti F, Alessandri C, Perricone C, Scrivo R, Rezai S, Ceccarelli F, et al. Neurocognitive dysfunction in systemic lupus erythematosus: association with antiphospholipid antibodies, disease activity and chronic damage. PLoS ONE. 2012;7(3):e33824.PubMed PubMedCentral CrossRef
26.Juby A, Davis P, Genge T, McElhaney J. Anticardiolipin antibodies in two elderly subpopulations. Lupus. 1995;4(6):482–5.PubMed CrossRef
27.Mosek A, Yust I, Treves TA, Vardinon N, Korczyn AD, Chapman J. Dementia and antiphospholipid antibodies. Dement Geriatr Cogn Disord. 2000;11(1):36–8.PubMed CrossRef
28.Hughes GRV. Migraine, memory loss, and “multiple sclerosis”. Neurological features of the antiphospholipid (Hughes’) syndrome. Postgrad Med J. 2003;79(928):81–3.PubMed PubMedCentral CrossRef
29.Iñiguez C, Pascual C, Pardo A, Martinez-Castrillo JC, Alvarez-Cermeño JC. Antiphospholipid antibodies in migraine. Headache. 1991;31(10):666–8.PubMed CrossRef
30.Cavestro C, Micca G, Molinari F, Bazzan M, DI Pietrantonj C, Aloi R, et al. Migraineurs show a high prevalence of antiphospholipid antibodies. J Thromb Haemost JTH. 2011;9(7):1350–4.PubMed CrossRef
31.Rajan R, Ahluwalia J, Lal V. Prothrombotic states in migraine. Clin Appl Thromb Off J Int Acad Clin Appl Thromb. 2014;20(8):851–6.CrossRef
32.Hering R, Couturier EG, Steiner TJ, Asherson RA, Clifford RF. Anticardiolipin antibodies in migraine. Cephalalgia Int J Headache. 1991;11(1):19–21.CrossRef
33.Williams FMK, Cherkas LF, Bertolaccini ML, Murru V, Surdulescu GL, Hughes GRV, et al. Migraine and antiphospholipid antibodies: no association found in migraine-discordant monozygotic twins. Cephalalgia Int J Headache. 2008;28(10):1048–52.CrossRef
34.Tsakiris DA, Kappos L, Reber G, Marbet GA, Le Floch-Rohr J, Roux E, et al. Lack of association between antiphospholipid antibodies and migraine. Thromb Haemost. 1993;69(5):415–7.PubMed
35.Tietjen GE, Day M, Norris L, Aurora S, Halvorsen A, Schultz LR, et al. Role of anticardiolipin antibodies in young persons with migraine and transient focal
neurologic events: a prospective study. Neurology. 1998;50(5):1433–40.PubMed CrossRef
36.Intiso D, Crociani P, Fogli D, Grandone E, Cappucci G, Di Rienzo F, et al. Occurrence of factor V Leiden mutation (Arg506Gln) and anticardiolipin antibodies in migraine patients. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2002;22(6):455–8.
37.Cuadrado MJ, Khamashta MA, Hughes GR. Migraine and stroke in young women. QJM Mon J Assoc Physicians. 2000;93(5):317–8.CrossRef
38.Stojanovich L, Kontic M, Smiljanic D, Djokovic A, Stamenkovic B, Marisavljevic D. Association between non-thrombotic
neurological and cardiac
manifestations in patients with antiphospholipid syndrome. Clin Exp Rheumatol. 2013;31(5):756–60.PubMed
39.••
Cervera R, Serrano R, Pons-Estel GJ, Ceberio-Hualde L, Shoenfeld Y, de Ramón E, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2015;74(6):1011–8. Provide strong epidemiologic data from the largest prospective cohort of APS patients.PubMed CrossRef